WO2023180982A1

WO2023180982A1 - Cosmetic use of a lavandin extract as a protective or anti-fatigue cosmetic agent

Info

Publication number: WO2023180982A1
Application number: PCT/IB2023/052869
Authority: WO
Inventors: Joan ATTIA; Romain DUROUX
Original assignee: International Flavors & Fragrances Inc.
Priority date: 2022-03-24
Filing date: 2023-03-23
Publication date: 2023-09-28
Also published as: FR3133755A1

Abstract

The present invention relates to the cosmetic field, in particular to cosmetic agents for controlling the effects of fatigue on the skin. The invention particularly relates to a liposoluble lavandin extract obtained by maceration in a terpene solvent as an anti-fatigue cosmetic agent for increasing the skin production of melatonin at the level of the healthy skin, as well as to cosmetic ingredients and cosmetic compositions containing same, and to cosmetic methods using same.

Description

COSMETIC USE OF AN EXTRACT OF VANDIN AS A PROTECTIVE OR ANTI-FATIGUE COSMETIC AGENT

TECHNICAL AREA

The present invention relates to the cosmetic field, in particular to cosmetic agents for combating the effects of fatigue on the skin.

TECHNOLOGICAL BACKGROUND

The skin is the first barrier protecting the body from external aggressions. This organ is made up of several layers of tissue. We distinguish the epidermis which is the outermost part of the skin, the dermis, a connective tissue made up of fibroblasts and an extracellular matrix, which ensures the functions of cohesion and nutrition of the skin, and the hypodermis made up of of adipocytes.

The epidermis is made up of several cellular layers of keratinocytes. We distinguish, among others, the germinative layer of the epidermis, called basal layer, containing, in particular, skin stem cells, the spinous layer, Stratum spinosum, made up of several layers of polygonal cells, the granular layer, Stratum granulosum, comprising one to three layers of flattened cells containing cytoplasmic inclusions, the keratohyalin grains, and finally, the stratum corneum, Stratum corneum which is composed of anucleated and keratin-rich cells called comeocytes which correspond to the terminal stage of differentiation of keratinocytes.

The outermost cells of the stratum corneum are continually shed and replaced by cells from a lower layer, in a process called desquamation. Cellular regeneration of the stratum corneum is based on a process of cellular maturation in which the cells of the basal layer of the epidermis differentiate and gradually migrate through the different strata of the epidermis until arriving at the stratum corneum below. the form of comeocytes.

The skin is generally the first to show signs of fatigue. Fatigue can be caused by many factors, such as lack of sleep, poor or unbalanced diet, overwork, intense or unsuitable activity at work, or disruptions in the family sphere. Women who combine family life and work, and young working people in urban areas are particularly exposed to chronic fatigue.

Individuals exposed to such fatigue may present with drawn features, loss of radiance of the complexion or even a dull complexion, dark circles and bags around the eyes. In other words, their face appears tired and marked, even sickly. However, projecting the image of a fit person can be a major concern for active individuals working, particularly in a competitive environment and/or in contact with customers.

Nevertheless, there remains, at present, a need for new cosmetic active ingredients to prevent or treat the visible effects of fatigue on the skin.

SUMMARY OF THE INVENTION

The invention relates to the cosmetic use of an extract, preferably fat-soluble, of lavandin obtained by maceration of lavandin plant material in a terpene solvent, as a protective cosmetic agent or anti-fatigue cosmetic agent for healthy skin. .

Preferably, the extract according to the invention is used as an anti-fatigue agent for healthy skin.

Lavandin extract is typically an extract of a hybrid chosen from Lavandula angustifolia Mill. x Lavandula latifolia Med k., Lavandula hybrida, and Lavandula x intermedia. Fat-soluble lavandin extract can be used as an anti-fatigue cosmetic agent to increase skin production of melatonin in healthy skin.

According to a particular aspect, the fat-soluble extract of lavandin can also be used as a cosmetic agent for resynchronizing or preventing non-pathological alteration of the circadian rhythm of healthy skin, and/or as a cosmetic agent for promote or promote skin protection mechanisms during the sleep phase in healthy skin.

According to an additional aspect, the lavandin extract according to the invention can be used to improve sleep, in particular to increase the total duration of sleep, and/or reduce the time awake after falling asleep in a tired subject.

Preferably, the fat-soluble extract of lavandin according to the invention is used in a tired individual, in whom fatigue is not associated with or caused by a pathological condition.

For example, fatigue in the individual can be caused by one or more factors chosen from lack of sleep, jet lag, poor or unbalanced diet, alcohol consumption, lack or excess of physical activity, sedentary lifestyle, overwork, intense or unsuitable activity at work, activity at night or at odd times, exposure to screens, and stress.

Lavandin extract can be used to treat or prevent one or more signs of skin fatigue chosen from a loss of radiance of the skin, a dull complexion, a dull complexion, a loss of uniformity of the complexion, facial features. tight face, dark circles around the eyes, bags on the eye level, swollen eyelids, loss of elasticity, loss of density, loss of firmness, and combinations thereof.

In other embodiments, the lavandin extract can be used to treat or prevent one or more signs of skin fatigue chosen from loss of skin radiance, dull complexion, dull complexion, loss of uniformity of complexion, tight facial features, dark circles around the eyes, bags around the eyes, swollen eyelids, and their combinations. The extract can also be used as a cosmetic agent to promote or improve skin protection against environmental stress.

In certain embodiments, the extract is further used to improve sleep, in particular to increase the total duration of sleep, and/or reduce the time awake after falling asleep. In other embodiments, the extract is used as a cosmetic agent to resynchronize or prevent alteration of the circadian rhythm of the skin, in particular following exposure to environmental stress. The extract can also be used to increase the production of melatonin in the skin.

In certain embodiments, the lavandin extract comprises at least 8.0% sesquiterpene compounds, the percentage corresponding to the percentage of area represented by the peaks of the sesquiterpene compounds relative to the total area of the peaks of the chromatogram obtained by GC/FID analysis of the absolute. The lavandin extract may in particular comprise from 10.0% to 20.0% of sesquiterpene compounds chosen from beta-caryophyllene, trans beta-famesene, gamma cadinene and alpha-bisabolol. at most 30.0%, preferably 6.0% to 18.0%, linalool, at least 3.5% lavandulyl acetate, preferably 4.0% to 7.0% acetate of lavandulyl. the percentage corresponding to the percentage of area represented by the peaks of the sesquiterpene compounds relative to the total area of the peaks of the chromatogram obtained by GC/FID analysis of the absolute.

In certain embodiments, the extract according to the invention can be obtained, or obtained, by a process comprising:

- a step comprising the maceration of lavandin plant material, preferably flowering tops, in a terpene solvent, the recovery of the liquid phase after maceration and the elimination of the terpene solvent from this liquid phase so as to obtain a concrete , And

- a step of eliminating the waxes present in the concrete so as to obtain the extract. The terpene solvent used in the process may comprise at least 85%, preferably at least 90% by weight of terpene compounds.

In certain embodiments, the extract is present as a cosmetic active agent in a cosmetic composition, preferably a cream, a balm, a mask, or a serum.

Typically said cosmetic composition comprises from 0.0005 to 0.05%, preferably from 0.001% to 0.01% by weight of said extract. The cosmetic composition can be chosen from the group consisting of aqueous solutions, hydroalcoholic solutions, oil-in-water (O/W) or water-in-oil (W/O) or multiple emulsions (triple: W/O/ W or O/W/O), nanoemulsions, in particular O/W nanoemulsions, aqueous gels, or dispersions of a fatty phase in an aqueous phase using spherules, suspensions, preferably in media aqueous or hydroalcoholic, suspensions of liposomes, powders, lotions, milks, creams, ointments, gels, foams, and ointments.

The invention also relates to a cosmetic process for preventing or treating signs of skin fatigue in a tired individual, said process comprising the application of a cosmetically effective quantity of an extract as defined above to the skin.

Typically, lavandin extract is present in a cosmetic composition as defined in the present application. In certain embodiments, the cosmetic process is used to prevent, treat or reduce dark circles and the extract is applied to the eye area. The cosmetic process can be implemented in an individual presenting fatigue, said fatigue not being caused or associated with a pathological condition. According to an additional aspect, the invention relates to a cosmetic ingredient comprising a lavandin extract as defined in the present application, in a cosmetically acceptable vehicle. For example, the cosmetic ingredient may comprise, or consist of, 0.1% to 1.5% by weight of said lavandin extract in a cosmetically acceptable vehicle chosen from pentylene glycol or triheptanoin.

The lavender extract is present in the cosmetic ingredient as an anti-fatigue cosmetic agent to increase skin production of melatonin in healthy skin and/or to resynchronize or prevent non-pathological alteration of the circadian rhythm of the skin. healthy skin, and/or as a cosmetic agent to promote or favor skin protection mechanisms during the sleep phase in healthy skin.

According to an additional aspect, the subject of the invention is a cosmetic composition comprising lavandin extract as defined in the present application, or a cosmetic ingredient as defined in the present application, in combination with at least acceptable excipient on the plan. cosmetic. The cosmetic composition can be chosen from the group consisting of aqueous solutions, hydroalcoholic solutions, oil-in-water (O/W) or water-in-oil (W/O) or multiple emulsions (triple: W/O/ W or O/W/O), nanoemulsions, in particular O/W nanoemulsions, aqueous gels, or dispersions of a fatty phase in an aqueous phase using spherules, suspensions, preferably in media aqueous or hydroalcoholic, suspensions of liposomes, powders, lotions, milks, creams, ointments, gels, foams, and ointments.

The cosmetic composition can be a treatment for use in the treatment or prevention of skin fatigue, for example a serum, a cream, a mask or a balm, preferably at night.

According to an additional aspect, the subject of the invention is the use of a lavandin extract or a cosmetic ingredient as defined in the present application in the manufacture of an anti-fatigue cosmetic composition to increase the skin's production of melatonin in healthy skin and/or to resynchronize or prevent non-pathological alteration of the circadian rhythm of healthy skin, and/or to promote or favor skin protection mechanisms during the sleep phase in the skin healthy.

Each of the aspects and embodiments described herein is capable of being used together, unless this is explicitly excluded or clearly excluded from the context of the embodiment or aspect considered.

FIGURES

Figure 1 represents the protective effect of the lavandin extract according to the invention with respect to UV stress on the expression of different genes involved in circadian rhythmicity in an ex-vivo study carried out on explants. of skin.

Figure 2 shows the effect of skin application to the face of the lavandin extract according to the invention on the total duration of sleep.

Figure 3 shows the effect of skin application to the face of the lavandin extract according to the invention on the duration of wakefulness after the onset of sleep.

Figure 4 shows the results of evaluation of dark circles at T12h, D7 and D28 in relative percentage compared to DO for the group treated with the “active” cream (Extract according to the invention) and the group treated with the placebo cream.

Statistical analysis: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

DETAILED DESCRIPTION Melatonin is a hormone produced by the pineal gland (also called the epiphysis). Melatonin secretion is inhibited in the presence of light and stimulated when it is dark. Through melatonin, the pineal gland informs the brain about the relative durations of the hours of darkness and light over a 24-hour period (daily cycle), but also throughout the year (seasonal cycle). Melatonin is called the “sleep hormone” and plays a central role in the regulation of chronobiological rhythms. This hormone is produced in different tissues. The process begins with Tryptophan which is converted into serotonin via different enzymes to finally transform the latter into melatonin by the successive action of Arylalkylamine N-acetyltransferase and hydroxyindole-O-methyltransferase.

Melatonin can act on the skin via 2 different pathways: receptor-independent and receptor-dependent. Melatonin is capable of playing a role as a cellular antioxidant, in particular by directly trapping free radicals, but also indirectly by increasing the activity of antioxidant enzymes. This molecule, which has the potential to cross cell membranes, also acts to maintain and protect mitochondrial activity. Melatonin also has beneficial effects on the skin by activating melatonin receptors. Melatonin receptors are G protein-coupled receptors that exist in two subtypes in humans, namely MT1 and MT2. They are expressed in the brain but also at the peripheral level, particularly in the skin.

As a peripheral tissue located at the interface between the internal and external environments, the skin performs critical functions for the preservation of the body's homeostasis, in coordination with environmental changes. Some of these functions undergo daily variations, such as temperature or water loss, suggesting the presence of their own circadian rhythm.

The Applicant was interested in a particular lavandin extract, obtained by extraction using a terpene solvent. This extract, and its method of obtaining, are described in the French patent application with filing number 20 05014 (Publication number: FR 3 110 422). Application FR 3 110 422 describes that this extract can be used as a soothing agent for the skin, in particular to relieve skin discomfort.

Surprisingly, the Applicant has shown that this type of extract has other cosmetic activities, very different from those described in application FR 3 110 422. The Applicant has thus shown that this type of extract was capable of increasing significantly the expression of melatonin by keratinocytes in vitro. The Applicant has also shown that Lavandin extract was capable of preventing the increase in the expression of clock genes such as Cry2 and Per2 in skin explants induced after UV irradiation. The same effect was observed for the Neatl and Neatl-2 genes which play a determining role in the regulation of these clock genes. The lavandin extract according to the invention is thus capable of resynchronizing or preventing alteration of the circadian rhythm of the skin, for example induced by exposure to environmental stress such as excessive exposure to UV.

Quite surprisingly, the Applicant has shown that the application of lavandin extract in a very low concentration to the skin makes it possible to improve the quality of sleep in individuals with mild sleep disorders due to their lifestyle. of life, in particular by increasing the total duration of sleep and reducing the time awake after falling asleep.

Finally, the Applicant has also shown that the extract according to the invention was capable of significantly reducing dark circles around the eyes in individuals with disturbed sleep cycles.

Thus, all of these results support the topical cosmetic use of the lavandin extract according to the invention as an anti-fatigue agent, that is to say to treat or prevent the skin signs of fatigue. , or as a protective agent for the skin, in particular to protect it against an alteration or desynchronization of the circadian rhythm following environmental stress.

Lavandin extract according to the invention

The invention relates to the cosmetic uses of lavandin extracts obtained by extraction using a terpene solvent. The extract according to the invention may in particular be a lavandin absolute. The lavandin extract according to the invention is preferably fat-soluble.

“Lavandula” means any plant species belonging to the genus Lavandula. Lavandula species include lavender species as well as hybrids thereof, including lavandin.

Lavender species include, but are not limited to, Lavandula angustifolia Mill, (also known as true lavender), Lavandula latifolia Medik. (also known as spike lavender), and Lavandula stoechas L. (also known as butterfly lavender).

By “lavandin” we mean Lavandula hybrids, that is to say hybrids of plants belonging to the Lavandula genus, and in particular lavender hybrids. Lavender species include, but are not limited to, Lavandula angustifolia Mill, (also known as of true lavender), Lavandula latifolia Medik. (also known as spike lavender), and Lavandula stoechas L. (also known as butterfly lavender). Preferably, lavender hybrids correspond to hybrids resulting from the crossing of true lavender and aspic. These hybrids are known as Lavandula angustifolia Mill, x Lavandula latifolia Medik., Lavandula hybrida, and Lavandula x intermedia. There are several varieties of lavandin including the Abrialis, Grosso, Super and Sumian varieties.

In a preferred embodiment, the lavandin extract used according to the invention is a lavandin absolute obtained by maceration in a terpene solvent.

The extract used according to the invention can in particular be the absolute as described in application FR No. 20 05014, and/or can be obtained by the process as described in said application.

Specifically, the extract according to the invention can be obtained from one or more aerial parts of a lavandin plant. It may be an extract obtained from the stems, flowers and/or flowering tops of a lavandin plant. In certain embodiments, the lavandin plant can be derived from organic farming.

In a preferred embodiment, the extract is obtained from flowering tops, preferably fresh, of lavandin.

The lavandin extract according to the invention is cosmetically acceptable, that is to say it is not toxic when used at usual concentrations in cosmetic products.

As indicated above, the extract according to the invention is typically an absolute.

In the context of the present invention, the term “absolute” means any fat-soluble extract of plant material that can be obtained by a process comprising: a) a step of extracting the plant material with a volatile solvent so as to obtain a concrete containing both odorous molecules and waxes, and b) a step of eliminating the waxes present in the concrete so as to obtain the absolute. In the context of the present invention, step a) is preferably carried out by maceration of the plant material from a lavandin plant in a terpene solvent.

The term “terpene solvent or solvent rich in terpene compounds” means a solvent having a content of at least 80%, preferably at least 85%, 90%, 95%, 98%, 99% or even 100% in weight of terpene derivatives.

It is preferably a terpene solvent which can be at least partially or completely eliminated from the maceration medium by distillation under reduced pressure at a temperature below 150°C. The terpene solvent is preferably liquid at room temperature (for example at 20-25°C).

By “terpene derivatives” we mean terpenes and their derivatives, in particular terpenoid compounds. Terpenes correspond to hydrocarbons resulting from the combination of several isoprene units. They are divided into several classes of compounds depending on the number of isoprene units they contain. Terpenes include monoterpenes, sesquiterpenes, diterpenes and triterpenes. Terpenes can be cyclic or acyclic.

Terpenoids are derivatives of terpenes comprising additional functional groups, including in particular an oxygen (for example an ester, alcohol, ketone or even etheroxide function) and/or less alkyl groups (for example one less methyl). Terpenoids include, but are not limited to, terpene alcohols (or monoterpenols), terpene ketones and aldehydes, terpene ethers, and terpene esters. Just like terpenes, terpenoids are divided into several classes of compounds depending on the number of isoprene units they contain. Terpenoids can be cyclic or acyclic.

In a particular embodiment, at least 60% by weight of the terpene compounds present in the terpene solvent are chosen from the group consisting of monoterpenes, monoterpenoids and mixtures thereof. For example, the monoterpenes and monoterpenoids can represent at least 80%, preferably at least 85% or even 90%, 95% or 98% by weight of the terpene compounds present in the terpene solvent. Preferably, the monoterpenoid compounds present in the solvent are chosen from monoterpenols and monoterpenol acetates.

As an example of monoterpenes, we can cite ocimenes, myrcene, limonene, alpha-pinene, beta-pinene, camphene, terpinolene, and p-cymene.

As an example of monoterpenoids, mention may be made of terpene alcohols such as linalool, eucaplyptol, menthol, nerol, geraniol, citronellol, borneol, terpineols and acetate esters thereof, or also terpene ketones and aldehydes such as citral, geranial, citronellal, camphor, and carvone.

The terpene solvent may consist of a mixture of terpene compounds, or be essentially composed (i.e. at least 95%, 96%, 98%, 99% or 100%) of a single terpene compound.

Preferably, it is a solvent comprising a mixture of terpene compounds, in which the monoterpenes and monoterpenoids represent at least 80% by weight, of preferably at least 90% or even at least 95% by weight of the total terpene compounds present in the solvent.

The terpene solvent may be a synthetic solvent, that is to say a solvent in which at least one of the terpene compounds it comprises has been prepared by chemical synthesis.

In a preferred embodiment, the terpene solvent is a natural solvent, that is to say a solvent prepared from a plant, animal or microbial material. In other words, it is a biosourced solvent.

In a particular embodiment, the terpene solvent is prepared by a process for extracting a natural material, preferably a plant material known to contain terpene compounds, in particular monoterpene compounds. It may be a raw material coming from a plant belonging to the Lamiaceae family, for example mint, sage, thyme, oregano, lavender, lavandin, rosemary, to the Pinaceae family. notably pines (genus Pinus), or the Rutaceae family, particularly species of the Citrus genus, for example lemon or orange trees. The starting plant material, which is used to prepare the terpene solvent, may consist of bark, berries, flowers, leaves, zest, resins in particular resinous oleoresins, rhizomes, roots, wood , seeds, needles, or even cell cultures, seedlings, and their combinations. For example, it may be a terpene solvent prepared by extraction of a pine oleoresin, by extraction of bark or zest of citrus fruits or even by extraction of flowers and/or leaves of a plant of the Lamiaceae family.

The terpene solvent can be prepared using any extraction process making it possible to recover the volatile terpene compounds of interest, in particular monoterpenes and monoterpenoids. The extraction process may comprise one or more fractionation steps such as one or more solid-liquid extraction steps, using a volatile organic solvent, a subcritical or supercritical fluid extraction step, in particular by supercritical CO2, a mechanical extraction step, in particular by cold expression, one or more distillation steps, for example hydrodistillation, distillation by steam distillation, fractional distillation or molecular distillation and combinations of those -this. Several extraction and/or purification techniques can be combined to obtain a terpene solvent enriched in volatile monoterpene compounds. In certain embodiments, the terpene solvent is a certified organic natural solvent, that is to say it has been prepared by an extraction process from a raw material originating and certified from organic farming. . Step a) can be carried out in the following manner: The plant material, preferably the flowering tops of lavandin, is covered with a terpene solvent as defined above. The plant material is left to macerate at a temperature between 40°C and 60°C at least for 90 min, generally for 60 to 120 min.

A sufficient volume of solvent is used to cover the plant material. The volume of solvent to use is generally 1 to 10 liters per kg of plant material per maceration cycle and can vary depending on the starting plant material and the extractor used. After maceration, the liquid phase is recovered.

The maceration step can be repeated, typically 1 to 5 times, e.g. 1, 2 or 3 times. At the end of the first maceration, the plant material is recovered and returned to macerate in fresh or recycled solvent. After maceration, the liquid phase is recovered and combined with the liquid phase recovered at the end of the first maceration. A terpene solvent of the same composition is preferably used in the different maceration stages. The maceration time may be shorter in the additional maceration step(s).

The terpene solvent is removed from the liquid phase by distillation under reduced pressure and is generally recycled for further extraction. The distillation residue constitutes the concrete which is in a pasty or solid form rich in odorous molecules and waxes.

Step b) aims to eliminate the waxes present in the concrete in order to obtain the absolute, that is to say the desired extract. Different strategies can be used to eliminate waxes, i.e. obtaining the absolute on one side and the waxes on the other.

The absolute can be recovered by carrying out a fractional extraction of the concrete by supercritical CO2: the constituent molecules of the absolute are entrained by the supercritical fluid and selectively recovered by modulating the temperature and pressure of the supercritical fluid.

An alternative solution is to eliminate waxes by taking advantage of their difference in hot and cold solubility in alcohol. In this case, the concrete is taken up in an alcohol or a hydroalcoholic solution titrated to at least 90% alcohol. The solution obtained is homogenized, if necessary hot (for example at a temperature below 60°C) then cooled so as to precipitate the waxes. Waxes can be removed by filtration. The absolute is then obtained from the filtrate collected by eliminating the alcohol, for example by concentration under vacuum.

During step b), part of the odorant molecules of interest may be trapped in the precipitated waxes, and therefore lost. In order to improve the absolute yield, an additional step can be carried out aimed at recovering the odorous molecules trapped in the precipitated waxes. Typically, the precipitated waxes are taken up in alcohol or in the hydroalcoholic solution, homogenized hot, precipitated cold and filtered. The filtrate obtained is combined with the filtrate from step b). This step can be repeated until satisfactory wax exhaustion is obtained.

The alcohol used in step b) and in the possible wax exhaustion step can be any type of lower C2-C5 alcohol, in particular ethanol or an alcoholic solution titrated at 90% alcohol. Preferably, a biosourced ethanol (i.e. a bioethanol) or a hydroalcoholic solution comprising at least 90% by volume of biosourced ethanol is used in step b).

Steps a) and/or b) can be repeated as necessary, for example to increase yield.

The process for preparing the extract (or absolute) of lavandin according to the invention may comprise one or more additional steps to those previously cited, in particular steps of washing and/or grinding the starting plant material or even additional purification steps for example by supercritical CO2 extraction, molecular distillation or fractional distillation, by precipitation and/or by extraction, in particular liquid-liquid or solid-liquid extraction.

In certain embodiments, the process does not include additional purification steps in steps a) and b).

The process may also include a step of formulating the extract, for example by adding one or more cosmetically acceptable excipients, in particular a cosmetically acceptable vehicle or support. For example, the extract used according to the invention can be diluted in a suitable organic or vegetable solvent, for example triethyl citrate, glycerol, propylene glycol, pentylene glycol, triheptanoin, or a vegetable oil from an oleaginous plant. , encapsulated in a vectorization system, for example liposomes or even adsorbed on a solid vehicle.

As indicated above, in a preferred embodiment, the lavandin extract is obtained by maceration of plant material derived from lavandin, preferably from lavandin flowering tops.

In a particular embodiment, the lavandin extract used according to the invention comprises at least 8% sesquiterpene compounds. Preferably, the lavandin extract comprises from 10.0% to 20.0% of sesquiterpene compounds chosen from beta-caryophyllene, trans beta-famesene, gamma cadinene and alpha-bisabolol. The lavandin extract used according to the invention may in particular comprise from 3.0% to 7.0% of beta-caryophyllene, from 1.0% to 4.0% of bisabolol, at least 2.0% of trans -beta farnesene and at least 0.5% gamma-cadinene,

In certain embodiments, the lavandin extract used according to the invention comprises less than 30.0%, preferably less than 25.0% of linalool, eucalyptol, camphor and borneol. The linalool content is typically less than 20.0%, preferably 6.0% to 18.0% or 8.0% to 16%.

The extract used according to the invention may further comprise at least 3.5% lavandulyl acetate, preferably from 4.0% to 7.0% lavandulyl acetate. The absolute may also comprise at least 20%, preferably 25% to 40% linalyl acetate.

The percentages mentioned above correspond to the percentage of peak area (or peaks) corresponding to the chemical compound of interest (or chemical compounds of interest) relative to the total area of the peaks of the chromatogram obtained by GC analysis /FID, preferably carried out according to the conditions described in Example 2.

In certain embodiments, the extract according to the invention (also called absolute according to the invention) comprises: from 10.0% to 20.0%, sesquiterpene compounds chosen from beta-caryophyllene, trans beta-famesene , gamma cadinene and alpha-bisabolol. at most 30.0%, preferably 6.0% to 18.0%, linalool, at least 3.5% lavandulyl acetate, preferably 4.0% to 7.0% acetate of lavandulyl. the percentage corresponding to the percentage of area represented by the peaks of the sesquiterpene compounds relative to the total area of the peaks of the chromatogram obtained by GC/FID analysis of the absolute.

Uses according to the invention

The subject of the invention is the cosmetic, non-therapeutic use of lavandin extract as described above as a protective or anti-fatigue agent for the skin, and more particularly, to treat or prevent a or several signs of skin fatigue.

The lavandin extract according to the invention is typically incorporated into a cosmetic composition before being applied to the skin.

For the purposes of the invention, the terms "skin" and "cutaneous" refer to any part of the skin of the human body, in particular the skin of the face, including the lips and eyelids, the neck, and the skin of the hands. Preferably, this is the skin on the face, including the eye contour and the lip contour, and on the neck.

In the context of the present invention, said lavandin extract is typically applied topically, preferably to skin or mucous membranes. This is healthy skin or mucous membrane, that is to say skin or mucous membrane that does not have wounds or skin pathologies. In particular, said lavandin extract, or the cosmetic composition comprising it, is applied to non-acne skin (that is to say not suffering from acne), which does not present wounds, in particular resulting insect bites, or skin infections, e.g. caused by a fungus (mycosis), a bacteria or a protozoa. In other words, the extract or composition used according to the invention does not produce a therapeutic effect on the skin, when it is used according to the invention.

The extract according to the invention is used as an agent having a cosmetic effect on the skin.

The term “cosmetic effect” means any non-therapeutic effect, aimed at modifying and/or improving the appearance of the skin or mucous membranes such as the lips, or at protecting them from external aggressions (sun, wind, humidity, dryness, products chemical), for example to prevent and/or correct phenomena linked to aging or to prevent or treat non-pathological effects caused by fatigue on the skin.

In certain embodiments, the term “cosmetic effect” means any non-therapeutic effect, aimed at modifying and/or improving the appearance of the skin or mucous membranes such as the lips.

According to certain embodiments, a “cosmetic effect” does not include the fact of protecting the skin and mucous membranes from external aggressions (sun, wind, humidity, dryness, chemicals), and/or preventing and/or correcting phenomena linked to their aging.

According to other embodiments, the extract according to the invention is not used to provide an anti-aging effect, in particular anti-wrinkle, and/or a soothing or protective effect on sensitive, reactive and/or topical skin.

The term “anti-fatigue agent” means a cosmetic agent capable of preventing, treating or alleviating the “cutaneous effects or signs” of fatigue, that is to say the effects of fatigue on the skin.

In the context of the present invention, the term “cutaneous signs or effects” means any non-pathological alteration or modification of the visual appearance or mechanical properties of the skin. In the context of the present invention, “skin signs or effects” are caused by, or associated with, fatigue. “Preventing a sign or effect” means delaying or preventing the appearance of said sign or effect on the skin. By “treating a sign or effect” is meant the act of reducing, attenuating, blurring, correcting or slowing down the development of said sign or effect on the skin. The sign(s) of skin fatigue may for example be a loss of radiance of the skin, a dull complexion, a blurred complexion, a loss of uniformity of the complexion, drawn facial features, dark circles around the eyes, eye bags, swollen eyelids, loss of elasticity, loss of density, loss of firmness, appearance of fine lines or wrinkles, and combinations thereof.

In a preferred embodiment, the sign(s) of skin fatigue may for example be a loss of radiance of the skin, a dull complexion, a blurred complexion, a loss of uniformity of the complexion, tight facial features, dark circles around the eyes, bags around the eyes, puffy eyelids, and combinations of these.

In one aspect, the sign(s) of skin fatigue does not include loss of elasticity, loss of density, loss of firmness, appearance of fine lines or wrinkles, and combinations thereof. Preferably, the skin effect(s) of skin fatigue are chosen from a loss of radiance of the skin, a dull complexion, a blurred complexion, a loss of uniformity of the complexion, tight facial features, dark circles on the eyes, bags around the eyes, and swollen eyelids.

In certain embodiments, the Lavandula absolute used according to the invention can be used for at least one (1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of the following purposes: a ) Prevent, treat or reduce dark circles and/or bags around the eyes, b) Prevent, treat or reduce swelling of the eyelids, c) Prevent, treat or reduce pigmentation irregularities of the skin, including pigment spots induced by fatigue, d) Homogenize or unify the facial complexion, e) Make the facial complexion brighter and/or more radiant and/or clearer, f) Prevent or treat a dull complexion, a dull complexion and/or drawn features, g) Make the skin, particularly on the face, fresher and more luminous, h) Soothe the facial features, i) Make the appearance of the skin less tired, more relaxed, fresher j) Make the look less tired, more rested and brighter, k) Promote or accelerate the recovery of the epidermis, particularly on the face, l) Revitalize the skin, particularly on the face, m) Promote a healthy glow, n) Prevent, treat, or reduce a loss of firmness of the skin, particularly on the face, and/or o) Prevent, treat, delay, or reduce the appearance of wrinkles or fine lines.

It goes without saying that the non-pathological alterations listed above are associated with or caused by fatigue on the skin.

In the list above, the preferred cosmetic effects sought are one or more effects a)-g) and i)-m).

In the context of the present invention, the fatigue causing non-pathological modifications or alterations of the skin can be of any type. It may be temporary or chronic fatigue. This includes fatigue caused by one or more factors, particularly environmental. This may be due to factors such as lack of sleep, for example due to the pace of work or the family situation (e.g. birth of a child), sleep disorders or jet lag, poor hygiene poor or unbalanced diet, alcohol consumption, lack or excess of physical activity, sedentary lifestyle, overwork, intense or unsuitable activity for work, activity at night or during odd hours, significant exposure to screens , stress, anxiety or anxieties linked to professional or family life.

Fatigue can also result from physiological situations such as pregnancy or menopause.

Preferably, fatigue is not associated with or caused by a medical condition in the individual. In the context of the present invention, the term "protective agent" means a cosmetic agent capable of maintaining the circadian rhythm of the skin and/or preventing an alteration of the circadian rhythm of the skin, in particular induced by stress, for example stress. environmental such as exposure to the sun, wind, humidity, drought or chemicals or processes such as abrasion, rays, etc. or even stress linked to lifestyle (jet lag , lack of sleep, night work etc.)

By maintaining the circadian rhythm of the skin, in particular by preventing alterations in the circadian rhythm of the skin, the extract according to the invention makes it possible to indirectly prevent skin effects caused by fatigue or caused by exposure to environmental stress. or resulting from lifestyle.

The Extract according to the invention is capable of preventing the increase in the expression of clock genes such as Cry2 and Per2 in skin explants subjected to UV irradiation. The same effect was observed for the Neatl and Neatl-2 genes which play a determining role in the regulation of these clock genes. According to another aspect, the lavandin extract according to the invention is used to maintain or prevent alteration of the circadian rhythm of the skin, for example induced by exposure to environmental stress, for example excessive exposure to UV. Said lavandin extract can also be used as a cosmetic agent to resynchronize the skin's circadian rhythm. In particular, the lavandin extract according to the invention can be used to regulate the expression of genes involved in the circadian cycle such as the clock genes Cry2, and Per2, and/or Neatl and Neatl-2.

It has also been shown that said lavandin extract is capable of increasing the expression of melatonin in keratinocytes. Thus, in a particular embodiment, said lavandin extract can also be used as a cosmetic agent to increase the production of melatonin at the skin level. The lavandin extract according to the invention can be used as an agent for potentiating the effect of melatonin on the skin. As illustrated in the examples, the application of said lavandin extract to the skin at a very low concentration, notably not perceptible by smell, helps improve sleep.

In an additional or alternative aspect, said lavandin extract is used to improve sleep, in particular to increase the total duration of sleep and/or reduce the time awake after falling asleep (also called WASO for “Wake time After Sleep Onset”). .

According to an additional embodiment, said lavandin extract is used to promote or favor skin protection mechanisms during the sleep phase.

According to an additional aspect, said lavandin extract is used as a protective or anti-fatigue skin agent in an individual exposed to fatigue, in particular chronic fatigue.

In a preferred embodiment, the extract according to the invention is not applied to so-called sensitive, reactive, or intolerant skin, or even with an atopic tendency.

“Sensitive, reactive or intolerant skin” means skin characterized by disproportionate reactivity to external factors which causes skin discomfort. This increased reactivity may result from a non-pathological alteration of the barrier function of the skin which reduces the skin's tolerance threshold towards external stimuli. The term “atopic-prone skin” means sensitive skin in an individual who has suffered from atopic dermatitis, and/or has an allergic background, that is to say having a history of allergy and/or having a family history of allergy. More generally, the absolute according to the invention is not used in as an anti-inflammatory agent or as a soothing or calming agent, that is to say an agent capable of relieving, namely reducing or preventing, skin discomfort.

In the uses according to the invention, the lavandin extract is incorporated as a cosmetic active agent in a cosmetic composition, preferably a cream, a balm, a mask, a serum or a lotion, as described below. After. The concentration of said extract in such a cosmetic composition is advantageously low, so that it is not perceptible by smell. Typically, this concentration is 0.0005% to 0.05% by weight, preferably 0.001% to 0.01% by weight of said absolute.

It goes without saying that the uses according to the invention are intended for individuals exposed to fatigue as defined above. The individuals covered by the present invention can be of any age and gender. In a preferred embodiment, this is an individual under the age of 65. This may be, for example, a woman or a man aged 25 to 65, particularly 25 to 55. For example, this is a woman aged 25 to 45 years old.

Cosmetic compositions used according to the invention

The lavandin extract described in the present application is typically incorporated as a cosmetic agent, more precisely as a regenerating, repairing or anti-fatigue agent. In other words, said extract is typically applied to the skin of the individual to be treated via a cosmetic composition.

A cosmetic ingredient or a precursor composition comprising said extract can be prepared beforehand to then be incorporated into the cosmetic composition.

Such a cosmetic ingredient or such a precursor composition may for example be a composition comprising from 0.1% to 1.5% by weight, preferably from 0.2 to 1.0% by weight, of lavandin extract such as described in the present application, in a cosmetically acceptable vehicle.

The cosmetically acceptable vehicle may be of any type. For example, it may be a cosmetically acceptable solvent in particular lower alcohols including ethanol, isopropanol, dipropylene glycol, butylene glycol, propanediol, glycerin, sorbitol, propylene glycol, pentylene glycol, triheptanoin, an aqueous solution thereof, or a mixture thereof.

Preferably, said vehicle is pentylene glycol or triheptanoin.

In a particular embodiment, the cosmetic ingredient according to the invention essentially consists of or consists of the lavandin extract according to the invention in a cosmetically acceptable vehicle chosen from pentylene glycol or triheptanoin. The extract from Lavandin is preferably present in a content of 0.1% to 1.5% by weight relative to the total weight of the cosmetic ingredient.

The cosmetic composition used according to the invention comprises said lavandin extract, preferably as a cosmetic agent, or the cosmetic ingredient or said precursor composition described above, in combination with at least acceptable excipient on the plan. cosmetic.

The cosmetically acceptable excipient(s) present in the composition may be chosen from diluting agents, dispersing agents, gelling agents, emollients, vectoring agents (such as polycationic polymers, phospholipids, unilamellar liposomes or multilamellar, niosomes, ethosomes, lamellar systems, nanosomes, lipid or polymeric vesicles, nanospheres, micro or nano-particles of natural or non-natural polymers, hydrogels), gums, resins, solvents in particular lower alcohols including ethanol, isopropanol, dipropylene glycol, butylene glycol, propanediol, glycerin, sorbitol, and propylene glycol, fillers such as modified and polymerized starches, titanium dioxide, or a metal stearate, preservatives, essential oils, pearlescent agents, colorants, odor absorbers, pH regulating agents or neutralizing agents, lubricating agents, thickening agents, hydrotropes such as surfactants including anionic, cationic, amphoteric or non-ionic surfactants, humectants, wetting agents, stabilizing agents, bulking agents, dispersing agents, perfumes, organic or even mineral pigments such as iron oxides, oily agents such as oils or fats of vegetable origin, fats of animal origin, synthetic oils such as petroleum jelly, silicone oils (cyclomethicone), fatty alcohol esters, fluorinated oils, waxes, modified clays, bentones, metallic fatty acid salts, silica, polyethylenes, mica, preservatives, antimicrobial agents, vehicles such as mineral, thermal or floral water, and/or other substances commonly used in formulation in the cosmetic or pharmaceutical field.

In one embodiment, the cosmetic composition comprises from 0.0005 to 0.05%, preferably from 0.001% to 0.01% by weight of said lavandin extract.

More particularly, said cosmetic composition may comprise:

- from 0.0005% to 0.05% by weight, preferably from 0.001% to 0.01% by weight of said lavandin extract, and

- from 99.95% to 99.9995% by weight of one or more cosmetically acceptable excipients. In another embodiment, said cosmetic composition comprises from 0.5% to 5% by weight, preferably from 0.5% to 2% by weight, of said precursor composition.

More particularly, said cosmetic composition may comprise:

- 0.5% to 5% by weight, preferably 0.5% to 2% by weight of said precursor composition, and

- from 95% to 99.5% by weight of one or more cosmetically acceptable excipients. In certain embodiments, the cosmetic composition further comprises one or more active agents with additional cosmetic effect(s). The term “active ingredient with cosmetic effect, active agent with cosmetic effect, cosmetic agent or active ingredient with cosmetic effect” means a compound capable of exerting at least one cosmetic effect on the skin or its annexes. The term “cosmetic effect” means any non-therapeutic effect aimed at modifying and/or improving the visual appearance and mechanical properties of the skin or mucous membranes such as the lips, to protect them from external aggressions (sun, wind, humidity, dryness). , chemicals), to prevent and/or correct phenomena linked to aging, or to prevent or treat the effects caused by stress or fatigue on the skin.

Examples of such agents are, among others, anti-wrinkle agents, anti-aging agents, antioxidant agents, moisturizing agents, soothing agents, anti-redness agents, decongestant agents, scrubbing or exfoliating agents, mattifying agents, sebum-regulating agents, lightening active ingredients, anti-dark spot active ingredients, anti-dark circles or anti-puffiness agents, anti-stress agents, anti-fatigue agents, anti-pollution active ingredients, tightening agents, filters and sunscreens, and their combinations.

In particular, the cosmetic composition may comprise tocopherols, and/or plant extracts such as flaxseed extracts, Vibrio exopolysaccharide extracts, peptides such as trifluoroacetyl tripeptide-2.

In a particular mode, the cosmetic composition may comprise an active ingredient chosen from an anti-wrinkle agent, an anti-redness agent, an antioxidant agent, a moisturizing active ingredient, a soothing agent, a sebum-regulating agent, an anti-spot or lightening agent, a tightening agent, an anti-pollution active ingredient, an anti-ceme or anti-puffiness agent, a filter or sunscreen, and combinations thereof.

As an example of anti-pollution agents, we can cite extracts of Chrysanthellum Indicum, polysaccharides, in particular marine polysaccharides from an Alter omonas fermentation medium and Nigari salts. As an example of anti-cema agents, we can cite extracts of Chrysantellum Indicum or extracts and sulfated polysaccharides of algae, in particular Ascophyllum nodosum or Asparagopsis Armata.

As an example of moisturizing agents, mention may be made of urea, pidolic acid (PC A) and its derivatives, in particular its salts such as arginine PCA, chitosan PCA, its copper salts (Copper PCA ), magnesium (magnesium PCA), sodium (sodium PCA) or zinc, ethylhexyl PCA, calcium gluconate, hyaluronic acid and its salts and other glycosaminoglycans, frucose, glucose, isomaltose, lactose, trehalose, polydextrose, sucrose (Sucrose), maltitol, mannitol, sorbitol, xylitol and other carbohydrates and derivatives, polyethylene glycols such as PEG-7, PEG-8, PEG -10, PEG-12 or PEG-14, glycerin, propylene glycol, butylene glycol, betaine, citrulline, collagen and its derivatives, histidine, hydrolysates of silk, keratin or soy, plant extracts rich in polysaccharides and/or polyphenols, for example extracts of Aloe, cornflower (Centaurea cyanus), extracts rich in polysaccharides, in particular from fermentation media of marine microorganisms such as Alteromonas and combinations thereof .

As an example of anti-aging agents, we can cite ascorbic acid and its derivatives such as magnesium ascorbyl phosphate, glycosaminoglycans and their derivatives, Cyathea polysaccharides, collagen, flaxseed extracts. (Linum usitatissimum), peptides such as Caprooyl-Tetrapeptide-3 and trifluoroacetyl tripeptide-2, extracts of Polygonum aviculare, extracts of brown algae, in particular of Ascophyllum nodosum, extracts of ferns, in particular of Cyathea cumingii.

As an example of anti-stress agents, we can cite the Rosality™ products (combination of rose water and a rose essential oil) and pink flower cistus extract, for example marketed under the IBR-Chill™ brand.

As an example of soothing agents, we can cite Allantoin, extracts of aloe, birch (e.g. Betula a! ha), willow herb (Epilobium angustifolium), chestnut (e.g. Castenea saliva) , cornflower (e.g. Centaurea cyanus), centella (e.g. Centella asialica), horsetail (e.g. Equisetum arvense), fennel (e.g. Foeniculum vulgare), witch hazel (e.g. Hamamelis virginiana), ivy (e.g. e.g. Hedera helix), Chahiscus sabdariffa, lily (e.g. Lilium candidum), mallow (e.g. Malva sylvestris), lemon balm (e.g. Melissa officinalis), skullcap (e.g. Scutellaria baicalensis), mimosa (e.g. Mimosa tenuiflora), cinquefoil (e.g. Potentilla erecta), an oligosaccharide extract or an oligosaccharide, e.g. flax, peptides such as palmitoyl tripeptide-8, polysaccharide extracts, in particular exopolysaccharide extracts from the fermentation medium of Alter omonas and combinations thereof.

As an example of antioxidant agents, we can cite HMR (hydroxy methyl resorcinol), ascorbic acid and its derivatives, vitamin B9, histidine hydrochloride, or an extract of willow herb (Epilobium augustifolium). The active ingredients with an antioxidant and vitamin-type effect are generally used in a mass percentage of at least 1% relative to the total weight of the cosmetic composition.

As an example of sebum-regulating agents, we can cite flax lignans, rice powder, zinc gluconate, sarcosine, an extract of Cinnamomum zeylanicum bark, an extract of avocado, an extract of Backhousia citriodora and combinations of these.

As anti-redness agents, we can cite saponins, flavonoids, ruscogenins, esculosides, and extracts containing them, for example Rusais extracts, as well as certain essential oils, for example lavender or rosemary. .

As an example of anti-stain agents, we can cite extracts such as licorice (Glycyrrhyza glabra), jackfruit extract (Artocarpus heterophyllus), Rumex extract (R.occidentalis), plant extracts belonging to to the citrus genus, resveratrol, peptides such as oligopeptide-68, nonapeptide-1, kojic acid, magnesium ascorbyl phosphate and combinations thereof.

In a particular embodiment, said cosmetic composition comprises from 0% to 30% by weight, for example from 0 to 15% by weight, of one or more additional cosmetic active agents.

In a more particular embodiment, said cosmetic composition comprises:

- from 0.0005% to 0.05% by weight, preferably from 0.001% to 0.01% by weight of said lavandin extract,

- from 69.95% to 99.9995% by weight of one or more cosmetically acceptable excipients, and

- from 0% to 30% by weight, for example from 0 to 15% by weight, of one or more additional cosmetic active agents.

In a more particular embodiment, said cosmetic composition comprises:

- 0.5% to 5% by weight, preferably 0.5% to 2% by weight of the precursor composition or the cosmetic ingredient as described above,

- from 65% to 99.5% by weight of one or more cosmetically acceptable excipients, and - from 0% to 30% by weight, for example from 0 to 15% by weight, of one or more additional cosmetic active agents.

The lavandin extract as described in the present application, the precursor composition, or the cosmetic ingredient comprising it, can be incorporated into any type of cosmetic composition. Preferably, it is a cosmetic composition having a form suitable for topical administration, in particular suitable for application to the skin. The cosmetic composition according to the invention can be of any type. In one embodiment, the cosmetic composition is chosen from the group consisting of aqueous solutions, hydroalcoholic solutions, oil-in-water (O/W) or water-in-oil (W/O) or multiple (triple) emulsions. : W/O/W or O/W/O), nanoemulsions, in particular O/W nanoemulsions, whose drop size is typically less than 100 nm, aqueous gels, or dispersions of a fatty phase in an aqueous phase using spherules, suspensions, preferably in aqueous or hydroalcoholic media, suspensions of liposomes, powders, lotions, milks, creams, ointments, gels, foams, balms, and ointments.

In particular embodiments, the cosmetic composition is a cream, a balm, a mask, a serum or a lotion. In a preferred embodiment, the cosmetic composition is a serum, a cream, a mask or a balm, preferably at night.

An additional object of the present invention is a cosmetic method for preventing or treating the signs of skin fatigue in an individual, said method comprising the application of a cosmetically effective quantity of lavandin extract as described above, or a cosmetic composition as described above on the skin.

The cosmetic process according to the invention aims to treat or prevent one or more skin effects of fatigue, preferably chosen from an alteration of the skin's complexion, in particular a blurred complexion, a dull complexion, a loss of radiance of the skin. complexion or a loss of uniformity of the complexion, in particular the appearance of pigment spots, drawn facial features, the appearance of bags and/or dark circles in the eyes, swollen eyelids, loss of density, loss of firmness, appearance of fine lines or wrinkles, and their combinations.

The method according to the invention can make it possible to obtain any of the following effects, in an individual exposed to fatigue:

- Prevent, treat or reduce dark circles and/or bags around the eyes,

- Prevent, treat or reduce swelling of the eyelids

- Prevent, treat or reduce pigmentation irregularities of the skin, including pigmentation spots induced by fatigue, - Homogenize or unify the facial complexion,

- Make the facial complexion brighter and/or more radiant and/or clearer,

- Prevent or treat a dull complexion, a blurred complexion and/or drawn features,

- Make the skin, particularly on the face, fresher and brighter,

- Soothe facial features,

- Make the skin look less tired, more relaxed, fresher

- Make the look less tired, more rested and brighter,

- Promote or accelerate the recovery of the epidermis, particularly on the face,

- Revitalize the skin, especially on the face,

- Promote a healthy glow, and/or

- Prevent, treat, delay, or reduce the appearance of fine lines or wrinkles,

In the list above, the preferred cosmetic effects sought are one or more effects a)-g) and i)-m)

In the cosmetic methods and uses according to the invention, the dose to be administered and the frequency of administration of the combination according to the invention vary depending on the desired cosmetic effect, the characteristics of the individual, in particular their sex , age and skin type. Typically, said lavandin extract, or the cosmetic composition comprising it, can be applied to the area to be treated once a day, preferably before bedtime, for several consecutive weeks or even several months, for example at least for 3 month. For example, the patient can apply a dose of 1 g to 2 g of cosmetic composition on his face in the evening.

General definitions:

Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art in the technical field of the present application.

This application is not limited by the example methods, uses and compositions described herein, and all methods, uses and compositions similar or equivalent to those described herein may be used in embodiments of the present application.

The headings and section titles provided herein should not be construed as limitations on the various aspects or embodiments of this application. Section headings and titles are used herein for organizational purposes only and should not be construed as limiting the invention described. All defined terms are more fully defined by reference to the application as a whole. All publications, including patent documents and scientific articles, referred to in this application are incorporated by reference in their entirety to the same extent as if each individual publication were individually incorporated by reference. Citation of such publications should in no way be construed as an admission that such publications constitute prior art. If any definition set forth in this application is contrary to or inconsistent with a definition set forth in the patents, applications, published applications and other publications which are incorporated herein by reference, the definition set forth in this application takes precedence over the definition which is incorporated by reference .

All features described in this application may be combined in any combination. Each characteristic described in this application may be replaced by another characteristic having the same, equivalent or similar objective. Thus, unless expressly stated otherwise, each feature disclosed is only one example of a generic series of equivalent or similar features.

Definitions of terms may appear throughout the description. It should be understood that this description is not limited to the particular embodiments described, as these may, of course, vary. It should also be understood that the terminology used herein is intended solely to describe particular embodiments and is not intended to be limiting.

It should be noted that, as used herein and in the appended claims, the singular forms "a", "an" and "the" include plural referents unless the context clearly indicates otherwise. For example, “one” or “an” includes “at least one” and “one or more.”

The terms “comprising”, “comprises” and “composed of” as used herein are synonymous with “including”, “includes”, “containing”, “contains”, and their grammatical variations. These terms are inclusive or open-ended and do not preclude additional members, elements, or process steps not cited from being present.

Where a range of values is provided, it is understood that each intermediate value between the upper and lower limits of this range is also specifically disclosed and encompassed in this description.

Other aspects and advantages of the present invention will appear on reading the examples which follow, which must be considered as illustrative and in no way as limiting.

EXAMPLES

Example 1: Preparation of a lavandin extract. Fresh flowering tops of lavandin (Lavandula angustifolia Mill x Lavandula latifolia Medik) from organic farming were macerated in a biosourced terpene solvent, also certified organic, comprising approximately 80 to 90% monoterpene compounds (approximately 2 to 10 L per kg of flowers) at a temperature of 50°C for at least 90 min. The mixture was decanted and the liquid phase and flowers were separated. The flowers were re-macerated once in the terpene solvent for 90 minutes, at 50°C. The liquid phases of the two macerations were combined and the terpene solvent was distilled under reduced pressure so as to obtain the concrete

The concrete was then taken up in ethanol. The mixture was homogenized, slightly heated then cooled so as to precipitate the waxes. The mixture was then filtered.

The filtrate was recovered. The waxes were taken up in ethanol. The mixture was homogenized while hot, cooled so as to precipitate the waxes and filtered. This step was repeated twice.

The collected filtrates are combined and the solvent evaporated under reduced pressure to obtain the extract (also called absolute). The overall return is generally between 9 and 16%.

Example 2: characterization of lavandin extract

- GC/FID analysis

The extracts are characterized by gas chromatography analysis coupled to a flame ionization detector (GC/FID). The conditions of the analysis are as follows:

GC/FID analyzes were performed with an Agilent 6890 instrument (Agilent Technologies) equipped with a flame ionization detector (FID), an automatic liquid sampler and an HP-1MS capillary column (100% dimethylpolysiloxane , 60 m x 0.15 mm i.d., film thickness 0.25 pm; Agilent Technologies). The oven temperature was maintained at 60°C for 10 min, then programmed from 60 to 300°C with 2°C/min, and finally 300°C for 10 min. The injector and detector temperatures were 250°C and 300°C, respectively; H2 (1.0 ml/min) as carrier gas; injection in split mode (1:50); volume injected 0.1 ml. The FID O2, H2, and makeup gas flow rates were 350, 35, and 20 mL/min, respectively.

The table below shows the distribution of volatile compounds present in the lavandin extract according to the invention. For each compound, the percentage indicated corresponds to the percentage of peak area corresponding to the chemical compound of interest relative to the total peak area of the chromatogram obtained by GC/FID analysis.

Table 1: Composition of a lavandin extract according to the invention (GC/FID analysis)

Example 3: Increased melatonin production in keratinocytes

The aim of this study was to detect the presence of melatonin in a cell culture of keratinocytes and to demonstrate that lavandin extract can increase the synthesis of the latter.

Protocol:

At t = 0, the keratinocytes were seeded in culture medium flasks and incubated for 5 days with renewal of the culture medium after 4 days. At t = 5 days, after amplification to reach ~20xl O ⁶ cells/vial, the medium was then replaced by treatment medium containing or not (control) the extract of Example 1 (0.0005%) and cells were incubated for 48 hours. All experimental conditions were carried out in n=2. At the end of the incubation, the culture supernatants were collected. The cells were detached and after a centrifugation step, the cell pellets were washed with phosphate-buffered saline (PB S) and frozen to dryness at −80 °C.

Melatonin was extracted from cell pellets and quantified by LC-MS/MS. After returning to room temperature, the pellets were washed twice with 250 μL of water and placed in a tube. An internal standard solution (100 pL), 1 mL of saturated saline (sodium chloride) solution, and 3 mL of dichloromethane were then added. The mixture was stirred at room temperature for 10 min and centrifuged for 3 min at 4500 rpm. The lower organic phase was collected and placed in a new tube. Dry evaporation under nitrogen at 40°C was then carried out. The upper aqueous phase was collected and 3 mL of dichloromethane was added. The mixture was stirred for 10 min at room temperature, and centrifuged for 5 min at 4500 rpm. The lower organic phase was recovered and pooled with the previous organic phase. Dry evaporation under nitrogen at 40°C was then carried out. The residue was suspended in 500 μL of methanol to dissolve it and then evaporated to dryness under nitrogen at 40°C. The residue was then suspended in 50 μL of methanol for analysis. The analytical method used was liquid chromatography coupled with MS/MS detection.

The equipment used was as follows: 1100 series HPLC system (Agilent) coupled to a CTC injector and a Quattro Micro API triple quadrupole mass spectrometer detector (Waters) Masslynx 4.0 software (Control, Acquisition, Implementation - Waters). The following parameters were retained: Column: RP18, Column temperature: 30°C, Mobile phase: Water + 0.2% acetic acid / Methanol + 0.2% acetic acid, Elution mode: Gradient, Injection volume: 20 pL, Run time: 20 minutes, MS detection: ESI, Polarity: Positive, Acquisition mode: MRM, Mass Transition m/z: Melatonin: 232

174;

Melatonin d4: 236 -> 177.

Results :

Melatonin was detected on NHEK cells with an average of 30.95 ng/20x10 ⁶ cells. When cells were treated with lavandin absolute, an increase of 2.10x10 ⁶ ng/cell (+6.8%) in melatonin was observed, compared to the control.

EXAMPLE 4: Modulation of circadian rhythm genes on skin explants

Protocol: The aim of this study was to evaluate the protective effect of the extract according to the invention on skin explants and to demonstrate its protective activity on different circadian rhythm genes of the skin.

On an abdominoplasty from a 46-year-old Caucasian woman (reference: P2471-AB46, phototype II-III (according to the Fitzpatrick classification of skin color), 51 explants with an average diameter of 11 mm (+ 1 mm) were prepared. The explants were kept alive in a BEM medium (BIO-EC's Expiants Medium) at 37°C in a humid atmosphere at 5% CÛ2 for 2 days. On day 0, day 1 and day 2, the explants were treated with the placebo (“E-UV” or “E” group) or the extract according to the invention (“Extract-UV” group) topically on the skin surface of the corresponding explants at a rate of 2pL per cm ² explant (~ 2mg/cm ² ). On day 2, the culture medium was then replaced by a solution of HBSS then the explants were irradiated (group “E-UV” and “extract-UV) or not (group “E”) by UV with a dose of 13.5 J/cm2 of UVA corresponding to 3 MED (minimum erythemal dose) and a dose of 0.15 J/cm2 of UVB corresponding to 1 MED. At the end of the irradiation, the culture medium was added in place of the HBSS. On day 3, the explants were fixed in RNAlater before RNA extraction using ReliaPrep™ RNA Tissue Miniprep System (fibrous) from Promega. The quality and concentration of the RNAs was assessed before performing the reverse transcriptase step with iScript (Bio-Rad, 20µl/reaction). With the help of a spike control, the ACq was calculated. The benchmarks evaluated for each qPCR reaction using CFX Manager 3.1 software are as follows:

-The logarithmic curve of the amplification for each sequence of interest.

-Melting curves are fluorescence intensities recorded after the last cycle. The temperature goes from 65° to 96°C with an increment of 0.5°C every 5 seconds.

-The curves representing the inverse of the derivative of the fluorescence signal as a function of temperature (in °C), make it possible to verify a single amplicon.

All samples were subjected to gene expression profiling analysis. For quantification, the number of cycles was normalized relative to the B2M reference gene:

(i) Cq (relative quantity) per sample and per gene = E (gene) (Cq (control) - Cq (treated)) E = efficiency of primer pairs = (% efficiency*0.01) + 1

Cq (control) = the quantitative threshold calculated by the CFX Maestro in “regression” mode for the control condition.

Cq (treated) = the quantitative threshold calculated by the CFX Maestro in “regression” mode for the treated condition. gene = target gene

(ii) Expression of a normalized target gene = NE

NE=Expression of normalized sample (gene) = Cq sample (gene) / ((Cq sample (ref 1) * Cq sample (ref 2)) ^1/n

Cq = relative quantity the denominator corresponds to the normalization factor including the two reference genes: ref 1 = B2M gene = target gene For each gene of interest, values were calculated between treatment samples in triplicate versus paired explant control samples in triplicate for each kinetic time point. A gene was considered induced if its expression showed an increase greater than or equal to 1.5 compared to the control (fold-change >1.5). Similarly, a gene was considered repressed if it showed a significant reduction in expression compared to the control. Additionally, when homogeneous gene modulation is retained between biological triplicates, a P value <0.05 (by T test) is indicated by an asterisk.

Results: During this study, it was found that UV induced a strong increase in the expression of the genes Cry2, Per2 as well as Neatl and Neatl-2, (E-UV control group, not treated with the extract according to the invention) compared to the condition without UV (group E). This effect was prevented by treating the explant with the extract according to the invention (Extract-UV group). Indeed, the extract made it possible to significantly prevent the increase in the expression of several genes regulating the circadian cycle such as Cry2, Per2 induced by exposure to UV, to tend towards the level of expression of the condition E. This demonstrates that the extract according to the invention makes it possible to protect the skin against deregulation of the skin's circadian cycle induced by environmental stress. In addition, a strong and significant inhibition of Neatl and Neatl-2 gene expression was also observed compared to the UV condition. These genes are notably involved in the regulation of circadian cycle genes to enable their rhythmicity.

All of these results support the use of the extract according to the invention as an anti-fatigue, skin-protecting agent (Figure 1).

Table 2: Results of gene modulation on skin explant

Example 5: Improved sleep

Protocol: 32 healthy participants (16 men, 22-56 years, median age 41.5 years) with self-reported mild sleep disturbances caused by lifestyle factors, but without a clinical sleep disorder diagnosis were been selected. The study consisted of the evaluation of 2 samples of facial cream, 1 “active” cream and a “placebo cream”, used separately over 3 weeks:

- “Active” cream: generic unscented cream for the face comprising 1% of a precursor composition comprising 0.5% by weight of the extract of Example 1, in pentylene glycol (A-Leen® 5, Minasolve ),

- “Placebo” cream: generic cream (see example 6, table 3 below) unscented for the face comprising 1% pentylene Glycol (A-Leen® 5, Minasolve) alone.

Devices: For objective sleep measures, participants used the SleepScore Max device (SleepScore Labs, Carlsbad, CA), a contactless monitoring device that uses breathing signal and motion detection to detect sleep and which has been validated by polysomnography (PSG), a standard method of measuring sleep. All self-report data were collected using Compusense, an online data collection software.

Study design and procedure:

- Contextual, randomized and counterbalanced study using an unscented control cream

- Participants applied the creams at bedtime, in their natural sleeping environment.

- The study lasted from Sunday evening to Friday morning for 3 consecutive weeks.

- Participants used a different sample each week. The control sample was used during the second week. Table 3 shows an overview of the study design.

- For each night of the study, participants completed daily questionnaires and tracked their sleep using the SleepScore Max device.

Table 3: protocol description

Data analyses:

Objective and self-reported nighttime sleep data were analyzed using JMP Pro statistical software (version 15) using a mixed model, across participants. A Alpha level of 0.05 was used for all statistical tests. The comparison was made between control and asset. The percentages come from calculations relative to the control condition. Statistical methods:

The data obtained and the percentage changes were subjected to the two-way Student's t test for paired data. The statistical significance value is p<0.05.

Results :

The lavandin extract according to the invention significantly increased the total duration of sleep (p <0.05) compared to the control. The participants slept on average for 6.6 hours (393 minutes) per night with the unscented control cream compared to 6.8 hours (408 minutes) with the cream containing the extract according to the invention. In addition, the wake time after falling asleep (also called WASO for “Wake time After Sleep Onset”) is on average 30 minutes per night with the unscented control cream compared to 25 minutes with the cream containing the extract according to the invention (Figures 2 and 3).

Example 6: Cosmetic products incorporating the extract used according to the invention

A) Night cream comprising 1% of a precursor composition comprising 0.5% by weight of the extract according to the invention prepared according to Example 1 in pentylene glycol

Table 4: Composition of the night cream B) Anti-fatigue cream comprising 1% a precursor composition comprising 0.5% by weight of the extract according to the invention prepared according to Example 1 in triheptanoin

Table 5: Composition of the anti-fatigue cream

Example 7: Clinical trial

Protocol: A clinical trial was carried out to confirm the anti-fatigue effect of the extract according to the invention on dark circles around the eyes. Forty-four volunteers were distributed evenly into two groups (22 individuals in the test group: “Active” cream and 22 individuals in the placebo group: Placebo cream).

The volunteers enrolled were people working shift schedules, young adults who were very socially active and used to going out and staying up late or traveling (jet-lag), or young mothers. The volunteers therefore had disturbed sleep cycles but were not treated for sleep disorders. The 2 creams were tested:

- “active” cream: generic unscented cream for the face comprising 1% of a precursor composition comprising 0.5% by weight of the extract of Example 1, in Triheptanoine (cream from Table 5 anti-fatigue below -Before), - “Placebo” cream: same generic unscented cream for the face but comprising 1% Triheptanoine alone (i.e. without extract).

The assessment of dark circles was carried out using original images taken with the Bio blue light scanner for each volunteer. The images were processed by specific software, and the rings were measured using the individual typology angle (ITA°) at different times: after 12 hours, after 7 days and after 28 days.

Statistical methods:

For each time, a statistical study was carried out to analyze the significance of the evolution of the parameters. The obtained data and percentage changes were subjected to two-way A-NOVA. The statistical significance value is p<0.05 ( ^#p <0.1;*p<0.05;**p<0.01;***p<0.001;****p<0.0001).

Results :

The result of the dark circles assessment is shown in Figure 4. Figure 4 shows a rapid, progressive and significant lightening of dark circles under the eyes in subjects treated with active cream compared to subjects treated with Placebo cream. Fat-soluble extract of lavandin according to the invention makes it possible to significantly reduce dark circles in subjects with disturbed sleep cycles.

The present invention is not intended to be limited in its scope to the particular embodiments described, which are provided, for example, to illustrate various aspects of the invention. Various modifications or variations of the compositions and methods described will become apparent from the description and teachings provided in the present applications. Such modifications may be made without departing from the true scope and spirit of this application and are intended to be included within the scope of this patent application. Although the invention may be described in relation to specific preferred embodiments, it is to be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, the different modifications or variants of the embodiments of the invention which are obvious to those skilled in the art in the cosmetic field or related fields are intended to fall within the scope of the following claims.

Examples of embodiments:

1. Cosmetic use of a lavandin extract obtained by maceration of lavandin plant material in a terpene solvent, as a protective cosmetic agent or anti-fatigue cosmetic agent for healthy skin. 2. Cosmetic use according to embodiment 1, characterized in that the lavandin extract is an extract of a hybrid chosen from Lavandula angustifolia Mill, x Lavandula latifolia Medik., Lavandula hybrida, and Lavandula x intermedia.

3. Cosmetic use according to embodiment 1 or 2, in which the lavandin extract is used to treat or prevent one or more signs of skin fatigue chosen from a loss of radiance of the skin, a dull complexion, a blurred complexion, loss of evenness of complexion, tight facial features, dark circles around the eyes, bags around the eyes, swollen eyelids, loss of elasticity, loss of density, loss of firmness , and their combinations.

4. Cosmetic use according to one of embodiments 1 to 3, in which the extract is used as a cosmetic agent to promote or improve skin protection against environmental stress.

5. Cosmetic use according to one of embodiments 1 to 4, in which the extract is further used to improve sleep, in particular to increase the total duration of sleep, and/or reduce the time awake after falling asleep .

6. Cosmetic use according to one of embodiments 1 to 5, in which the extract is used as a cosmetic agent to resynchronize or prevent alteration of the circadian rhythm of the skin, in particular following exposure to environmental stress.

7. Cosmetic use according to one of embodiments 1 to 6, in which the extract is used to increase the production of melatonin in the skin.

8. Cosmetic use according to one of embodiments 1 to 7, characterized in that the lavandin extract comprises at least 8.0% of sesquiterpene compounds, the percentage corresponding to the percentage of area represented by the peaks of the compounds sesquiterpenes relative to the total area of the peaks of the chromatogram obtained by GC/FID analysis of the absolute.

9. Cosmetic use according to one of embodiments 1 to 8, characterized in that the lavandin extract comprises

- from 10.0% to 20.0%, sesquiterpene compounds chosen from beta-caryophyllene, trans beta-farnesene, gamma cadinene and alpha-bisabolol.

- at most 30.0%, preferably from 6.0% to 18.0%, of linalool,

- at least 3.5% lavandulyl acetate, preferably from 4.0% to 7.0% lavandulyl acetate. the percentage corresponding to the percentage of area represented by the peaks of the sesquiterpene compounds relative to the total area of the peaks of the chromatogram obtained by GC/FID analysis of the absolute. 10. Cosmetic use according to one of embodiments 1 to 9, characterized in that the extract can be obtained by a process comprising:

- a step of eliminating the waxes present in the concrete in order to obtain the extract.

11. Cosmetic use according to one of embodiments 1 to 10, characterized in that the terpene solvent comprises at least 85%, preferably at least 90% by weight of terpene compounds.

12. Cosmetic use according to one of embodiments 1 to 11, in which the extract is present as a cosmetic active agent in a cosmetic composition, preferably a cream, a balm, a mask, or a serum.

13. Cosmetic use according to embodiment 12, in which the cosmetic composition comprises from 0.0005 to 0.05%, preferably from 0.001% to 0.01% by weight of said extract.

14. Cosmetic use according to one of embodiments 12 to 13, said cosmetic composition being chosen from the group consisting of aqueous solutions, hydroalcoholic solutions, oil-in-water (O/W) or water-in emulsions. oil (W/O) or multiple (triple: W/O/W or O/W/O), nanoemulsions, in particular O/W nanoemulsions, aqueous gels, or dispersions of a fatty phase in a phase aqueous using spherules, suspensions, preferably in aqueous or hydroalcoholic media, suspensions of liposomes, powders, lotions, milks, creams, ointments, gels, foams, and ointments.

15. Cosmetic method for preventing or treating signs of skin fatigue in an individual, said method comprising the application of a cosmetically effective quantity of an extract as defined in one of embodiments 1 to 2 and 8 to 11 on the skin.

Claims

1. Cosmetic use of a fat-soluble extract of lavandin obtained by maceration of lavandin plant material in a terpene solvent, as an anti-fatigue cosmetic agent to increase cutaneous production of melatonin in healthy skin.

2. Cosmetic use according to claim 1, wherein the extract is further used as a cosmetic agent to resynchronize or prevent non-pathological alteration of the circadian rhythm of healthy skin, and/or as an agent cosmetic to promote or favor skin protection mechanisms during the sleep phase in healthy skin.

3. Cosmetic use according to any one of claims 1 to 2, in which the extract is further used to improve sleep, in particular to increase the total duration of sleep, and/or reduce the waking time after falling asleep in a subject fatigue.

4. Cosmetic use according to any one of claims 1 to 3, in which the lavandin extract is used to treat or prevent one or more signs of skin fatigue chosen from a loss of radiance of the skin, a dull complexion, a blurred complexion, loss of evenness of skin tone, tight facial features, dark circles around the eyes, bags around the eyes, swollen eyelids, and their combinations.

5. Cosmetic use according to any one of claims 1 to 4, characterized in that the lavandin extract is an extract of a hybrid chosen from Lavandula angustifolia Mill, x Lavandula latifolia Medik., Lavandula hybrida, and Lavandula x intermedia.

6. Cosmetic use according to any one of claims 1 to 5, characterized in that the lavandin extract comprises at least 8.0% of sesquiterpene compounds, the percentage corresponding to the percentage of area represented by the peaks of the sesquiterpene compounds relative to Total peak area of the chromatogram obtained by GC/FID analysis of the extract.

7. Cosmetic use according to any one of claims 1 to 6, characterized in that the lavandin extract comprises - from 10.0% to 20.0%, of sesquiterpene compounds chosen from beta-caryophyllene, trans beta-farnesene, gamma cadinene and alpha-bisabolol.

- at most 30.0%, preferably from 6.0% to 18.0%, of linalool,

- at least 3.5% lavandulyl acetate, preferably 4.0% to 7.0% lavandulyl acetate. the percentage corresponding to the percentage of area represented by the peaks of the sesquiterpene compounds relative to the total area of the peaks of the chromatogram obtained by GC/FID analysis of the extract.

8. Cosmetic use according to one of claims 1 to 7, characterized in that the extract can be obtained by a process comprising:

9. Cosmetic use according to any one of claims 1 to 8, characterized in that the terpene solvent comprises at least 85%, preferably at least 90% by weight of terpene compounds.

10. Cosmetic use according to one of claims 1 to 9, in which the extract is present as a cosmetic active agent in a cosmetic composition, preferably a cream, a balm, a mask, or a serum.

11. Cosmetic use according to claim 10, in which the cosmetic composition comprises from 0.0005 to 0.05%, preferably from 0.001% to 0.01% by weight of said extract.

12. Cosmetic use according to one of claims 10 to 11, said cosmetic composition being chosen from the group consisting of aqueous solutions, hydroalcoholic solutions, oil-in-water (O/W) or water-in-oil emulsions ( W/O) or multiple (triple: W/O/W or O/W/O), nanoemulsions, in particular O/W nanoemulsions, aqueous gels, or dispersions of a fatty phase in an aqueous phase at with the help of spherules, suspensions, preferably in aqueous or hydroalcoholic media, suspensions of liposomes, powders, lotions, milks, creams, ointments, gels, foams, and ointments.

13. Cosmetic process for preventing or treating the signs of skin fatigue in a tired individual, said process comprising the application of a cosmetically effective quantity of a fat-soluble extract of lavandin obtained by maceration of a lavandin plant material in a terpene solvent on the skin.

14. Cosmetic process according to claim 13, in which the lavandin extract is as defined in any one of claims 5 to 9.

15. Cosmetic process according to claim 13 or 14, in which the lavandin extract is present in a cosmetic composition as defined in one of claims 10 to 12.

16. Cosmetic process according to any one of claims 13 to 15, in which the sign of skin fatigue is dark circles and in which the extract is applied to the eye contour.

17. Cosmetic process according to any one of claims 13 to 16, in which fatigue in the individual caused by one or more factors chosen from lack of sleep, jet lag, poor food hygiene or unbalanced, alcohol consumption, lack or excess of physical activity, sedentary lifestyle, overwork, intense or unsuitable activity at work, activity at night or at odd times, exposure to screens, and stress .

18. Cosmetic ingredient comprising a lavandin extract as defined in any one of claims 1 and 5 to 9 in a cosmetically acceptable vehicle

19. Cosmetic ingredient according to claim 18 comprising, or consisting of, 0.1% to 1.5% by weight of said lavandin extract in a cosmetically acceptable vehicle chosen from pentylene glycol or triheptanoin.

20. Cosmetic ingredient according to any one of claims 18 to 19, in which the lavandin extract is present as an anti-fatigue cosmetic agent to increase skin production of melatonin in healthy skin and/or to resynchronize or prevent non-pathological alteration of the circadian rhythm of healthy skin, and/or as a cosmetic agent to promote or favor skin protection mechanisms during the sleep phase in healthy skin.

21. Cosmetic composition comprising the lavandin extract according to one of claims 1 or 5 to 9, or the cosmetic ingredient according to one of claims 18 or 19, in combination with at least cosmetically acceptable excipient.

22. Cosmetic composition according to claim 21, said cosmetic composition being chosen from the group consisting of aqueous solutions, hydroalcoholic solutions, oil-in-water (O/W) or water-in-oil (W/O) emulsions or multiple (triple: W/O/W or O/W/O), nanoemulsions, in particular O/W nanoemulsions, aqueous gels, or dispersions of a fatty phase in an aqueous phase using spherules , suspensions, preferably in aqueous or hydroalcoholic media, suspensions of liposomes, powders, lotions, milks, creams, ointments, gels, foams, and ointments.

23. Cosmetic composition according to one of claims 21 or 22, said composition being a treatment for use in the treatment or prevention of skin fatigue, for example a serum, a cream, a mask or a balm, preferably of night.

24. Use of a lavandin extract according to one of claims 1 or 5 to 9 or of a cosmetic ingredient according to one of claims 18 or 19 in the manufacture of an anti-fatigue cosmetic composition to increase production cutaneous melatonin at the level of healthy skin and/or to resynchronize or prevent non-pathological alteration of the circadian rhythm of healthy skin, and/or to promote or favor skin protection mechanisms during the sleep phase at the level of healthy skin.